Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
The FDA expects to foster innovation and competition among manufacturers, which would lower the prices of hearing aids without compromising their quality.
Kate Hermans has taken over the reins of Ambrx as interim CEO following the abrupt departure of Feng Tian.
ScribeEMR, a leading provider of real-time remote medical scribe services, announces that it has surpassed its goal to provide remote scribe services on more than 80 EMR platforms, including the top three hospital EMRs and the top five EMRs used by outpatient practices.
Blueprint Medicines’ Ayvakit is headed to the FDA for a new indication after the drug hit the mark in Part 2 of the PIONEER trial for non-advanced systemic mastocytosis.
I-Mab quietly announced that its partner AbbVie is ending a Phase IB trial on lemzoparlimab for two types of cancers, despite a $2 billion deal inked in 2020.
All other ongoing and pending studies of Sanofi’s amcenestrant, including the early-stage breast cancer trial AMEERA-6, will also be discontinued.
BioSpace spoke with industry executives and investors about the current economic situation in the biotech industry and sourced tips on how leaders can weather the downturn.
The Bill & Melinda Gates Foundation inked a memorandum of understanding with South Korea’s foreign and health ministries to expand their partnerships revolving around public health.
Researchers found promising connections between the Neuregulin 4 (NRG4) endocrine factor protein and the suppression of specific liver diseases, including NASH.
Novavax seeks EUA for COVID-19 Booster, a 100-year-old TB vaccine may protect against the disease and public health officials struggle with fall planning.
Weeks after AstraZeneca and Daiichi Sankyo were able to move the bar in the treatment of metastatic breast cancer with Enhertu, Gilead is answering that challenge with Trodelvy.
Clene Nanomedicine’s CNM-Au8 demonstrated surprising improvements in some MS patients, despite the study being halted early due to COVID-19.
